Microbiome - Competitive Landscape, Technology and Pipeline Analysis, 2016; New Report Launched

Microbiome- Competitive Landscape, Technology and Pipeline Analysis, 2016 report provides comprehensive insights about pipeline drugs across microbiome. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Microbiome.

This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis of Microbiome at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Reports Highlights

• Microbiome Pipeline scenario
• Collaborations & partnering deals
• Current Prominent Research Areas and Key Players
• Pipeline product profiles Microbiome Technologies and Targeted Antigens
• Licensing opportunities
• Market Drivers and Barriers

Scope

• Overview of the global Microbiome pipeline scenario, products and associated companies information
• Coverage of global Microbiome under development
• Competitive landscape of products for key players
• Coverage of licensors, collaborators and Development partners, deal terms and deal values estimation
• Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
• Highlights of licensing & collaboration opportunities and funding details
• Highlights of latest Microbiome technologies and innovative companies

Spanning over 170 pages, 20 Tables and 21 Figures “Microbiome - Competitive Landscape, Technology and Pipeline Analysis, 2016” report covers Executive Summary Snapshot, Microbiome Overview, Pipeline Products Analysis, Pipeline Therapeutics, Comparative Analysis, Therapeutic Assessment, Appendix. This report Covered 12 Companies - Merck & Co., Inc., Ritter pharmaceuticals, ViThera Pharmaceuticals, Assembly Biosciences, Enterome Bioscience, Microbiome Therapeutics, Immuron, Quorum Innovations, Medarex, Inc., Bristol-Myers Squibb, Athersys, AstraZeneca plc.

For more information Visit at: http://mrr.cm/JRK

Find all Diseases Reports at: http://www.marketresearchreports.com/diseases